

Regd. Office :

'Zydus Tower',
Satellite Cross Roads,
Ahmedabad 380 015. India.
Phone : +91-79-2686 8100 (20 Lines)
Fax : +91-79-2686 8337

October 14, 2010

Bombay stock Exchange Limited

1st Floor, P.J. Towers
Dalal Street
MUMBAI – 400 001

Attention : Mr. Sanjay Golecha
Mr. Gopalkrishnan

Fax No. 022 – 22722039 / 3121

National Stock Exchange of India Ltd.

Exchange Plaza, 5th Floor,
Plot No. C/1, G Block
Bandra-Kurla Complex
Bandra – (East)
Mumbai – 400 051

Attention : Famroze Pochara
Asst. Vice President

Fax No. 022 – 26598237/38

Ahmedabad Stock Exchange Limited

Kamdhenu Complex
Opp. Sahajanand College
Panjara Pole,
Ahmedabad – 380 015

Attention : Mr. K. K. Mishra
Managing Director

Fax No. 079 - 26308877

Re. : Press release

Dear Sir / Madam

We are pleased to inform that Company has launched Pramipexole tablets (0.125 mg, 0.25 mg, 0.5 mg, 1 mg, 1.5 mg) in the US market upon patent expiry. The drug falls in the CNS segment and is used in the treatment of Parkinson's disease.

We enclose herewith a copy of Press Release dated 14th October 2010 titled “**Zydus Cadila launches Pramipexole Tablets in the US market**” to be released in the news papers which gives the full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors at large.

Thanking you,

Yours faithfully,

FOR CADILA HEALTHCARE LIMITED



**UPEN H. SHAH
COMPANY SECRETARY**

Encl.: As above.

Zydus Cadila launches Pramipexole Tablets in the US market

Ahmedabad, 14 October 2010

Zydus Cadila has launched Pramipexole tablets (0.125 mg, 0.25 mg, 0.5 mg, 1 mg, 1.5 mg) in the US market upon patent expiry. The drug falls in the CNS segment and is used in the treatment of Parkinson's disease.

The sales of Pramipexole tablets in 2010 as per NDC Health is estimated at USD 632 million.

The group has 56 approvals and has so far filed 113 ANDAs since the commencement of filing process in FY 2003-04.